Scholars Central

Conference abstractPublished 26 May 2017

Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in breast cancer: A meta-analysis

Authors: Guochao Zhang, Xue Qi, Likun Huang

Chinese Academy of Medical Sciences and Peking Union Medical College, China Shanxi Provincial PeopleâÂ?Â?s hospital, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Programmed death ligand-1 (PD-L1) is an immunological checkpoint protein that has recently been found to be associated with the prognosis of various malignancies. However, the association between PD-L1 expression and the survival of breast cancer patients has remained unclear. Therefore, the aim of the present meta-analysis was to assess the clinical value of PD-L1 in breast cancer patients. Methods: MEDLINE/PubMed, EMBASE, Cochrane Library, and Grey Literature databases were searched up to 30 March 2016 for articles involving an association between PD-L1 expression and breast cancer prognosis. Hazard ratios for overall survival with 95% confidence intervals (CIs) according to the expression status of PD-L1 were calculated. Odds ratios (ORs) were also analyzed to evaluate the association between clinicopathological parameters and PD-L1 expression. Results: Ten studies were included in this meta-analysis and 7 of these described clinicopathological features. Elevated levels of PDL1 were only significantly associated with histological grade (OR = 1.86, 95% CI: 1.38âÂ?Â?2.51; Pheterogeneity = 0.0196), estrogen receptor status (ER) (OR = 0.36, 95% CI: 0.17âÂ?Â?0.75; Pheterogeneity = 0.000), and progesterone receptor status (PR) (OR = 0.31, 95% CI: 0.11âÂ?Â?0.86; Pheterogeneity = 0.000). Conclusion: There were trends observed in the present meta-analysis, although PD-L1 status as a predictor of prognosis for patients with breast cancer could not be confirmed. Therefore, further studies of mechanism(s) related to PD-L1 expression level and immune escape and antitumor immune responses are needed, especially in relation to breast cancer subtypes. Furthermore, an evaluation standard for PD-L1 expression would facilitate all future studies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Breast Cancer: Current Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBreast Cancer: Current Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Guochao Zhang”
  • BylineArticles whose byline prints “Xue Qi”
  • BylineArticles whose byline prints “Likun Huang”